Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study

Author： Jankowitz Rachel   Abraham Jame   Tan Antoinette   Limentani Steven   Tierno Marni   Adamson Laura   Buyse Marc   Wolmark Norman   Jacobs Samuel  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.6, 2013-12, pp. : 1205-1212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer

By Osako Tomo   Ito Yoshinori   Takahashi Shunji   Tokudome Nahomi   Iwase Takuji   Hatake Kiyohiko  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 159-164

Springer Publishing Company

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

By Aogi Kenjiro   Masuda Norikazu   Ohno Shinji   Oda Takashi   Iwata Hiroji   Kashiwaba Masahiro   Fujiwara Yasuhiro   Kamigaki Shunji   Ito Yoshinori   Ueno Takayuki   Takashima Shigemitsu  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 829-838

Springer Publishing Company

Access to resources Recommend Favorite

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

By Livingston Robert   Barlow William   Kash Joseph   Albain Kathy   Gralow Julie   Lew Danika   Flaherty Lawrence   Royce Melanie   Hortobagyi Gabriel  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 123-131

Springer Publishing Company

Access to resources Recommend Favorite